Vacuna de Papiloma Humano

Cáncer de cuello del útero - VPH

La vacuna, VPH, Riesgos

Virus Papiloma

Cancer de Utero

Vacuna de Papiloma VPH

VPH es la abreviación de Virus de Paipilloma Humano, de acuerdo al Centro de Control de Enfermedades CDC, son un grupo de mas de 150 Virus relacionados, cada uno tiene un número para distinguir el tipo de VPH. El VPH es el nombre para las verrugas, los papilomas, que algunos tipos de VPH pueden causar.

Aproximadamente el 26% de las niñas y las mujeres de 14-59 años de edad tiene alguna cepa de VPH. En más del 90% de estos casos, el VPH desaparece por sí solo dentro de los dos años, sin causar ningún problema a la salud.

El CDC recomienda que niños de 11 a 12 años reciban dos dosis de esta vacuna, la segunda dosis dada de 6-12 meses después de la primera dosis. Gardasil 9 recomeinda 3 dosis en su prospecto.

Hay dos vacunas para el VPH: Cervarix y Gardasil, ambas contienen aluminio en una forma u otra, junto con otros ingredientes que se pueden ver este link. Gardasil 9 tiene 500 mcg de aluminio cada dosis, al ser 3 dosis el niño recibe 1500 mcg de aluminio, además del aluminio de otras vacunas.

Cervarix es una vacuna bivalente desarrollada para proteger contra la infección del VPH tipos 16, 18 e, estos son los responsables del 70 % de todos los cánceres de cuello uterino.

Aproximadamente el 2% de las mujeres y niñas han estado expuestos a estas dos cepas. Gardasil es una vacuna cuatrivalente con el objeto de impedir los tipos 6, 11, 16, y 18. Los tipos 6 y 11 son responsables del 90 % de todas las verrugas genitales.

El CDC recomienda esta vacuna para las niñas y niños a pesar de que según los Anales de Medicina: "En la actualidad no hay datos significativos que demuestren que Gardasil (Merck) o Cervarix (GlaxoSmithKline) puede prevenir cualquier tipo de cáncer de cuello uterino, ya que el período de prueba utilizado fue demasiado corto para evaluar los beneficios a largo plazo de la vacunación contra el VPH" 1.

  • 1. https://es.scribd.com/doc/127818325/Annals-of-Medicine-HPV-Vaccine
Diane Harper

En una entrevista de ABC News en septiembre del 2009, la doctora Diane Harper, que es una de los científicos que desarrolló la vacuna contra el VPH, admitió que:

“La tasa de eventos adversos graves, es mayor que la tasa de incidencia de cáncer de cuello uterino”.

La incidencia de cáncer cervical en los EE.UU. es tan baja que si tenemos la vacuna y continuamos haciendo las pruebas de Papanicolaou, no vamos a bajar la tasa de cáncer cervical en los EE.UU. Si se vacuna a un niña, no va a mantener la inmunidad en la pubertad, y no podremos prevenir el cáncer cervical.

Controles o Vacuna?

De 1000 mujeres que contraen una infección por VPH aproximadamente el 70 % de ellas van a auto sanarse dentro del 1er. año sin ayuda de nadie, no hay que detectarlo para hacer que se vaya el cuerpo se encarga de eso.

Dentro de los 2 años aproximadamente el 90% de todos esas infecciones van a desaparecer por sí mismas a los tres años quedan el 10% del grupo original de mujeres es decir unas 100 mujeres que tienen infecciones de HPV.

A los tres años, la mitad de esas infecciones (50 mujeres) han progresado en lo que llamamos una lesión CIN 23 o lesión precancerosa y entonces aproximadamente 5% de las infecciones por VPH terminan en una lesión precancerosa.

Entonces tenemos ese pequeño grupo de mujeres que con lesiones precancerosas recién entonces observamos un movimiento hacia carcinoma invasivo entonces sabemos que entre las mujeres con lesiones CIN 3 que es un poco más grave que el CIN 23 del otro grupo, toma 5 años para que un 20% de las infecciones de esas 50 mujeres se conviertan en carcinomas invasivos, es decir 10 mujeres como vemos, es un proceso muy lento y tarda unos 30 años para el 40%, 4 mujeres se conviertan en carcinomas invasivos de cuello uterino.

Entonces si según informe VAERS 2017 (ver en http://sanevax.org/vaers-report/) ya hubo 317 muertes, 50.467 Daños Graves y más 18.000 Hospitalizaciones, informados, que siempre es una cifra que se calcula hasta 10 veces menor de lo que realmente ocurre, para que vacunar y correr todos estos riesgos sabiendo que además la vacuna nunca ha demostrado curar un solo caso de cáncer cervical y tiene una eficiencia del 60 % y al eliminar solo algunos virus, da lugar al desarrollo de otros que toman el lugar de los eliminados causando cáncer tal vez más rápido que los eliminados? Tomando en cuenta que haciendose controles Papanicolau, se puede prevenir facilmente?

ver video

  • Active subtítulos en Español con cc, o activar el celular

Gardasil

En el prospecto de Gardasil 9 en el item 4.8 Reacciones adversas, Experiencia post-comercialización

Las siguientes reacciones adversas han sido notificadas espontáneamente durante el uso tras la aprobación de la vacuna VPHq y puede que también se observen en la experiencia postcomercialización con Gardasil 9.

  • Infecciones e infestaciones: Celulitis en el lugar de inyección.
  • Trastornos de la sangre y del sistema linfático: Púrpura trombocitopénica idiopática, linfoadenopatía.
  • Trastornos del sistema inmunológico: Reacciones de hipersensibilidad incluyendo reacciones anafilácticas/anafilactoides.
  • Trastornos del sistema nervioso: Encefalomielitis aguda diseminada, síndrome de Guillain-Barré, síncope acompañado algunas veces de movimientos tónico-clónicos
  • Trastornos gastrointestinales: Vómitos
  • Trastornos musculoesqueléticos y del tejido conjuntivo: Artralgia, Mialgia
  • Trastornos generales y alteraciones en el lugar de administración: Astenia, escalofríos, malestar general.

y en la version en ingles de la misma vacuna incluye muerte que en el prospecto en español no figura

  • Blood and lymphatic system disorders: Autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, lymphadenopathy.
  • Respiratory, thoracic and mediastinal disorders: Pulmonary embolus.
  • Gastrointestinal disorders: Nausea, pancreatitis, vomiting.
  • General disorders and administration site conditions: Asthenia, chills, death , fatigue, malaise.
  • Immune system disorders: Autoimmune diseases, hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria.
  • Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
  • Nervous system disorders: Acute disseminated encephalomyelitis, dizziness, Guillain-Barré syndrome, headache, motor neuron disease, paralysis, seizures, syncope (including syncope associated with tonic10 clonic movements and other seizure-like activity) sometimes resulting in falling with injury, transverse myelitis. ( se llamaba polio en los años 60)
  • Infections and infestations: Cellulitis.
  • Vascular disorders: Deep venous thrombosis.
    • Ver testimonio de Víctimas de esta vacuna Gardasil de Merck

    • http://sanevax.org/victims-2/gardasil-silgard-victims/
    gardasil

    Eventos Adversos

    En el motor de búsqueda Alerta Med, al 31 de diciembre, 2016, hubo un total de 43.532 informes sobre reacciones a la vacuna, realizadas al Sistema Federal informes Eventos Adversos de Vacunas asociadas a la vacuna (VAERS), incluyendo 250 muertes. La vacuna contra el VPH representan el 25% de todos los casos adversos de VAERS. El 4/3/2016 en el artículo publicado en la revista Vaccine, relativas a eventos adversos en Alberta, Canadá, con el seguimiento de 195.270 niñas después de recibir la vacuna contra el VPH, 19.351 de ellas, que es del 9,9 por ciento, terminaron en la sala de emergencias dentro de los 42 días de haber sido vacunados

    El Dr. Jesper Mehlsen encargado del control vacunas Gardasil de Merck en el Hospital Frederiksberg de Dinamarca dice: "La estimación real es que 1 de cada 500 niñas vacunadas con Gardasil experimentan serios efectos adversos".

    "Cuando se mira la literatura independiente, estudios que no están patrocinados por los fabricantes de vacunas, en relación con Gardasil ha habido varios informes que documentan la esclerosis múltiple y la encefalitis, que es la inflamación cerebral, en las niñas que han recibido su vacuna Gardasil. Tan sólo porque un estudio patrocinado por los fabricantes no identifica problemas con la vacuna no significa necesariamente que la vacuna es segura. De hecho, si uno mira a los estudios del fabricante, a menudo no están diseñados para detectar eventos adversos graves. Hubo un estudio realizado por un grupo de investigadores patrocinado por Glaxo Smith y Kline y estaban examinando Cervarix, que es otra vacuna contra el VPH, y los autores reconocieron que ninguno de los estudios que evaluaron han sido diseñados para detectar enfermedades autoinmunes. Así que obviamente, no ivan a encontrar lo que no estaban buscando. Y a pesar de estos obvios defectos, concluyeron que no hay evidencia de que Cervarix esté asociado con un mayor riesgo de enfermedades autoinmunes,esto es absurdo porque no lo estaban buscado, este estudio no estaba diseñado para detectar enfermedades autoinmunes. "

    - Dra. Lucija Tomljenovic, PhD, Becaria post-doctoral en la Universidad de Columbia Británica, donde trabaja en Neurociencias y el Departamento de Medicina

    El Dr. Sin Hang Lee es Patólogo, Director del Laboratorio Molecular Milford, Milford (Estados Unidos), Graduate Medical College de Wuhan, China. Enseñó en la Universidad de McGill y en la Universidad de Yale. Este es un experto internacional en el uso de secuenciación de ADN para el diagnóstico molecular. En su carta abierta, el Dr. Lee plantea una serie de preocupaciones serias sobre el programa de vacuna contra el VPH propuesto: "No hay evidencia científica de que las vacunas contra el VPH han demostrado prevenir un solo caso de cáncer de cuello uterino en cualquier país. Para promover la vacuna, se creó un temor innecesario al cáncer de cuello uterino para crear un mercado basado en el miedo y no realidad. Debido a la diferencia genética, las vacunas contra el VPH que originalmente fueron desarrolladas y probadas en América del Sur pueden no funcionar en diversas poblaciones étnicas.

    El control pap establecido y de bajo costo, es un medio seguro y efectivo comprobado de controlar el cáncer de cuello uterino y como tal debe ser el programa de salud número uno, ahorrando miles de millones de dólares e incontables vidas.

    La vacunación contra el VPH no ofrece ningún valor añadido a los programas existentes del control tradicional del cáncer cervical.

    Globalmente hay 10.000 reacciones adversas graves, incluyendo muertes, después de la vacunación contra el VPH

    Los fabricantes de vacunas han utilizado de manera inapropiada su adyuvante de aluminio altamente potenciador de la inmunogenicidad como placebo en todos los ensayos clínicos para ocultar el riesgo de vacunas contra el VPH. Las preocupaciones que el Dr. Lee tiene acerca de la vacunación contra el VPH se aplican en otros países, donde se están realizando varias investigaciones sobre seguridad y eficacia y los programas de vacunación han sido detenidos.

    El Dr. Bernard Dalbergue, que trabajó con el laboratorio Merck que son los que la fabrican. El Dr. Dalbergue entregó los detalles a una revista médica francesa, y al “Health Impact News Daily”, en extractos de la entrevista el médico confirma que Gardasil es inútil, cuesta una fortuna y que los tomadores de decisiones a todos los niveles son conscientes de ello. “Mi predicción es que Gardasil se convertirá en el mayor escándalo médico de todos los tiempos, porque en algún momento en el tiempo, la evidencia se suman a demostrar que esta vacuna, no tiene absolutamente ningún efecto sobre el cáncer de cuello de útero y que todos los muchos efectos adversos que destruyen vidas e incluso matan, no sirven para ningún otro propósito que la de generar ganancias para los fabricantes “, dice el doctor Dalbergue. Añade que hay cuantiosos intereses económicos por eso aun la vacuna no ha sido descartada. Los registros del gobierno documentan miles de reacciones adversas asociadas con la vacuna, incluyendo parálisis, convulsiones, ceguera y decenas de muertos.

    El Ministerio de Salud de Japón ha emitido un aviso de todo el país que las vacunas de cáncer cervical ya no deben ser recomendados para las niñas de 12 a 16 años, ya se han reportado varias reacciones adversas a los medicamentos. “Es necesario reunir información inmediatamente a captar con precisión la frecuencia (los efectos secundarios) se están produciendo”, dijo Mariko Momoi, que preside el panel de la Salud, Trabajo y Bienestar Ministerio que decidió suspender la recomendación. Momoi es vicepresidente de la Universidad Internacional de Salud y Bienestar.

    http://www.japantimes.co.jp/news/2013/06/15/national/cervix-vaccine-issues-trigger-health-notice/#.WRx5b-s1_IX

    ¿Qué es exactamente un placebo?

    placebo-aluminio

    Es un medicamento inocuo o inerte dado como un falso remedio al grupo de control en los experimentos sobre la eficacia de un fármaco o vacuna . Sabemos que, en los cuatro o cinco ensayos, los placebos de Gardasil contenían aluminio, que es una neurotoxina conocida. Ver prospecto de Gardasil. En los estudios de esta vacunas, si realmente se va a comparar los efectos secundarios en comparación con los que no la recibieron, se tendria que haber usado el placebo autentico. El placebo en vacunas, es solución salina y veo que en los estudios que se realizaron por Laboratorios Merck, la compañía que hace esta vacuna, en ves, el placebo era la misma dosis enorme de aluminio Dr. Paul Thomas Pediatra (AAP)

    ver video
    • Active subtítulos en Español con cc, o activar el celular

    Aluminio en las Vacunas Neurotóxico

    El aluminio en las vacunas no es el mismo aluminio se ingiere o inhala, el aluminio en las vacunas tiene una estructura tal que puede pasar fácilmente al cerebro, y llevar virus y bacterias, dado que se usa con el emulsionante en vacunas, llamado polisorbato-80. placebo-aluminio

    El polisorbato-80, es utilizado por la industria farmacéutica para lograr que los medicamentos pasen al cerebro a través de la barrera sangre-cerebro. También se usa en vacunas y se adhieren muy fuertemente al aluminio.

    El aluminio, como adyuvante, tiene un tipo de estructura que se liga fuertemente a las bacterias y a los virus y el polisorbato-80, que es el emulsionante, se une muy fuertemente al aluminio y a las bacterias y los virus y pueden entrar en el cerebro como si fueran un fantasma que puede pasar a través de una pared.

    La industria farmacéutica utiliza partículas como el aluminio que hay en las vacunas para unir las drogas, y conseguir que pasen a través de la barrera entre la sangre y el cerebro, porque sin esto las drogas no pasan a través de esta barrera.

    Entonces la industria farmacéutica utiliza el emulsionante Polysorbate-80 para ligarse a la nanopartícula, esa partícula de aluminio que está enlazado al fármaco para aumentar la entrada de ese fármaco en el cerebro, 20 veces.

    Esa misma tecnología que la industria farmacéutica utiliza para mejorar el suministro de fármacos a través de la barrera entre la sangre y el cerebro y asi entrar al cerebro es la misma tecnología que usa en las vacunas.

    Entonces conociendo la ciencia, debemos preguntarnos, qué ingredientes de la vacunas entran en el cerebro? no hay estudios... que materiales de las vacunas se supone entran al cerebro? No hay estudios...

    L. Palevsky

    Si materiales de la vacuna se meten en el cerebro, que sucede?

    • 1 de cada 6 niños contraen discapacidades de desarrollo neurológico
    • 1 de cada 50 con autismo
    • 1 de cada 10 con ADHD
    • 1 de cada 20, con menos cinco años con convulsiones, hasta que se demuestre lo contrario.

    En 2011, hubo un estudio publicado, donde investigaron más de 91.000 niños que demostró que el 54% de estos niños tenían al menos 1 de 20 enfermedades crónicas.

    Aquí estamos en el año 2016. empecé medicina en 1983 y aun no estamos analizando estos datos.

    Hay que hacer más pruebas con las vacunas que contienen sustancias como polisorbato-80 y asumir que están haciendo daño hasta que se demuestre lo contrario. De acuerdo con la hoja de seguridad de datos de materiales (MSDS) de sciencelab.com, Polisorbato-80 fue probado para la inhalación e ingestión, y demostró ser levemente peligroso en el caso de contacto con la piel.

    El MSDS no aborda los efectos de Polisorbato-80 a través de la inyección Sin embargo, en la misma sección de toxicología, en toxicidad crónica en los seres humanos establece y cito: "el Polisorbato-80 puede causar efectos adversos en la reproducción basado en datos con pruebas con animales.

    No existen datos sobre humanos, una evidente falta de investigación, sobre los efectos tóxicos del ingrediente Polisorbato-80 sobre la salud humana. hay quienes argumentan que los ingredientes como Polisorbato-80 en las vacunas son seguras y no son peligrosas, simplemente porque están presentes en las vacunas en cantidades minúsculas.

    El hecho es que el programa de vacunación del CDC manda a médicos a dar a los bebés y a los niños 49 dosis de vacunas antes de la edad de 6 años los resumenes del excipiente del CDC de la vacuna indican que la vacuna DTaP, la de gripe, meningococo, neumocócica, vacunas contra el rotavirus, y TDAP, todas contienen Polisorbato-80. ¿Cuáles son los efectos acumulativos de los ingredientes de múltiples vacunas?

    De acuerdo con el MSDS, Polisorbato-80 “puede causar cáncer de acuerdo a pruebas con animales” y “puede ser mutagénico.” se debería exigir a los fabricantes de vacunas y a la FDA proporcionar evidencia científica seria, demostrando que incluir Polisorbato-80 en vacunas para adultos y niños, es seguro.

    Expertos

    Cancer Cervical

    Stephanie Seneff

    PhD MIT

    Stephanie Seneff is a Senior Research Scientist at the MIT Computer Science and Artificial Intelligence Laboratory. She received the B.S. degree in Biophysics in 1968, the M.S. and E.E. degrees in Electrical Engineering in 1980, and the Ph.D degree in Electrical Engineering and Computer Science in 1985, all from MIT.

    In recent years, Dr. Seneff has focused her research interests back towards biology. She is concentrating mainly on the relationship between nutrition and health. Since 2011, she has written 10 papers (7 as first author) in various medical and health-related journals on topics such as modern day diseases (e.g., Alzheimer, autism, cardiovascular diseases), analysis and search of databases of drug side effects using NLP techniques, and the impact of nutritional deficiencies and environmental toxins on human health.

    Publicaciones

    S. Seneff, A. Lauritzen, R. Davidson, and L. Lentz-Marino. Is Endothelial Nitric Oxide Synthase a Moonlighting Protein Whose Day Job is Cholesterol Sulfate Synthesis? Implications for Cholesterol Transport, Diabetes and Cardiovascular Disease, Entropy 14, 2492-2530, 2012.
    A. Samsel and S. Seneff. Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases. Entropy 15, 1416-1463, 2013.

    Information on Glyphosate (Roundup)

    1. U.S. Congressional Hearing on Glyphosate, June 14, 2016. (Download Presentations from this link.)
    2. Presentation at the University of Belize on April 6, 2017. (Download)
    3. Glyphosate, Roundup, Glyphosate-Tolerance GM Soybeans, Chemical Extracted Soybean Food Oil/Soybean Powder Cause Serious Harm to Health of American/Chinese People. Compiled and translated by I-wan, Chen (cheniwan@cei.gov.cn). (Download)
    4. Glyphosate and Autism Slides presented at the Peoples' Assembly meeting in The Hague, Netherlands, October 14, 2016. (Powerpoint Slides)
    5. Is Roundup the Primary Cause of the Current Epidemic in Chronic Diseases? Slides for presentation hosted by Talk About Curing Autism (TACA), Massachusetts Chapter, Oct 1, 2016. (Powerpoint Slides)
    6. Connecting the Dots: Autism, MMR Vaccine and Roundup Honolulu, HI, February 22, 2017. Sponsored by Seeds of Truth and Kokua Market. (Powerpoint Slides) (PDF Version)
    7. Roundup, MMR and autism -- A Toxic Connection. Honolulu, HI, August 4, 2016. Sponsored in part by Seeds of Truth and Kokua Market. (Powerpoint Slides) (PDF Version)
    8. "GMOs & glyphosate -- real threats to human & environmental health." Presented at event at University of Toronto, April 28, 2016, sponsored by Science For Peace. (Powerpoint Slides) (PDF Version)
    9. Presentation on glyphosate at Environmental Health Symposium in San Diego in March, 2016. (Powerpoint Slides) (PDF Version)
    10. Glyphosate: The "Safe" Herbicide that's Making Us All Sick. July, 2015. Hawaii tour, sponsored in part by Seeds of Truth. (Video of Presentation) (Powerpoint Slides) (PDF Version)
    11. Roundup and GMO and the Rise of Modern Disease. Jan. 22, 2015. Talk in Honolulu, HI, sponsored by Seeds of Truth. (Powerpoint Slides) (PDF Version)
    12. Roundup and GMOs: Are We Gambling with the Future of Food? July 29, 2014, Talk presented at the National Cheng Kung University, Tainan, Taiwan (Powerpoint Slides) (PDF Version)
    13. Presentation at an Informational Hearing on Genetically Modified Organisms for the Agricultural and Rural Affairs Committee of the Pennsylvania legislature. (Powerpoint Slides) (PDF Version)
    14. Is Roundup the Toxic Chemical that's Making Us All Sick? June 5, 2014, Groton School, Campbell Performing Arts Center, Groton MA. (Powerpoint Slides) (PDF Version)
    15. "Sulfate Deficiency in Neurological Disease Following Aluminum and Glyphosate Exposure," Webinar presented on June 2, 2015, hosted by Jessica Sherman. (Powerpoint Slides) (PDF Version)
    16. Presentation on Wednesday, May 27, 2015 in Taiwan, organized by the Green Formosa Front and sponsored by the HaoRan Foundation. (Powerpoint Slides) (PDF Version)
    17. Presentation on glyphosate on April 28, 2014 hosted by the MIT and Wellesley Alumni Associations (Powerpoint Slides) (PDF Version)
    18. Presentation on March 26, 2014 at International Symposium on Vaccines in Nice, France: A Role for the Pineal Gland in Neurological Damage Following Aluminum-adjuvanted Vaccination (Powerpoint Slides) (PDF Version)
    19. Presentation on March 16, 2014 at Physicians' Roundtable Conference in Tampa, FL. (Powerpoint Slides) (PDF Version)
    20. Presentation on Oct 16, 2013 hosted by the Wellesley chapter of the League of Women Voters. Video. Slides.
    21. 326 page document by Sayer Ji - many references to the literature on why not to vaccinate. Click Here
    22. Nancy Swanson, Andre Leu, Jon Abrahamson and Bradley Wallet. Genetically engineered crops, glyphosate and the deterioration of health in the United States of America. Journal of Organic Systems, 9(2), 2014. Click Here
    23. Compilation (by Rosemary Mason MB ChB FRCA) of data worldwide on effects of glyphosate on human health. Click Here
    24. Former Monsanto employee put in charge of GMO papers at journal Click Here Scientific journal withdraws Seralini paper on Roundup toxicity Click Here
    25. Autism Rates and Glyphosate Application Rates to Corn and Soy in the U.S. as A Function of Time. Click Here
    26. Slides Presented to MIT Faculty at CSAIL Offsite Meeting on May 17, 2013, on autism and glyphosate. (Powerpoint Slides) (PDF Version)

    Papers in Refereed Journals on Nutrition and Disease

    Note: These papers collectively explain how sulfate deficiency throughout the body is behind most modern diseases and conditions, and how toxic chemicals in the environment cause this deficiency.
    1. A. Samsel and S. Seneff. "Glyphosate pathways to modern diseases VI: Prions, amyloidoses and autoimmune neurological diseases." Journal of Biological Physics and Chemistry 2017; 17: 8-32. (Download)
    2. J.E. Beecham and S. Seneff. "Autoimmune Disease: Budget-buster or Enlightened Solutions? (The coming epidemic and the new administration in Washington)." Arch Community Med Pub Health 2017;3(1):32-40. (Download)
    3. S. Seneff, W. Morley, MJ Hadden and MC Michener. "Does glyphosate acting as a glycine analogue contribute to ALS?" J Bioinfo Proteomics Rev 2016; 2(3): 1-21. (Download)
    4. D. Kennedy, S. Seneff, RM Davidson, JW Oller, Jr, BE Haley and RD Masters. "Environmental Toxicants and Infant Mortality in the USA." Peertechz J Biol Res Dev 2016;1(1): 036-061. (Download)
    5. S. Seneff, N. L. Swanson, G. Koenig and C. Li. "Is GERD a Factor in Osteonecrosis of the Jaw? Evidence of Pathology Linked to G6PD Deficiency and Sulfomucins," Disease Markers Volume 2016 (2016), Article ID 8376979. (Download)
    6. A. Samsel and S Seneff. "Glyphosate pathways to modern diseases V: Amino acid analogue of glycine in diverse proteins," Journal of Biological Physics and Chemistry 2016;16: 9-46. (Download)
    7. Nancy Swanson, Judy Hoy and Stephanie Seneff. "Evidence that glyphosate is a causative agent in chronic sub-clinical metabolic acidosis and mitochondrial dysfunction" International Journal of Human Nutrition and Functional Medicine 2016;4:32-52. (Download)
    8. Beecham JE and Seneff S. "Is there a link between autism and glyphosate-formulated herbicides?" J Autism 2016; 3:1. (Download)
    9. Seneff S, Swanson N, Li C, Koenig G. "Death as a Drug Side Effect in FAERS: Is Glyphosate Contamination a Factor?" Agricultural Sciences 2015;6:1472-1501. Agricultural Sciences 2015;6:1472-1501. (Download)
    10. Anthony Samsel and Stephanie Seneff. "Glyphosate, pathways to modern diseases IV: cancer and related pathologies," The Journal of Biological Physics and Chemistry 2015; 15:121-159. (Download)
    11. James Beecham and Stephanie Seneff. "The Possible Link between Autism and Glyphosate Acting as Glycine Mimetic - A Review of Evidence from the Literature with Analysis." Molecular and Genetic Medicine 2015; 9:4. (Download)
    12. Gerald Koenig and Stephanie Seneff. "Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk." Disease Markers Volume 2015 (2015): Article ID 818570. (Download)
    13. Judy Hoy, Nancy Swanson and Stephanie Seneff. "The High Cost of Pesticides: Human and Animal Diseases." Poult Fish Wildl Sci 2015; 3:1. (Download)
    14. Stephanie Seneff, Robert M. Davidson, Ann Lauritzen, Anthony Samsel, and Glyn Wainwright. "A novel hypothesis for atherosclerosis as a cholesterol sulfate deficiency syndrome." Theor Biol Med Model. 2015; 12: 9. (Download)
    15. Anthony Samsel and Stephanie Seneff. "Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies." Surgical Neurology International 2015; 6:45. (Download)
    16. Stephanie Seneff, Nancy Swanson and Chen Li. "Aluminum and Glyphosate Can Synergistically Induce Pineal Gland Pathology: Connection to Gut Dysbiosis and Neurological Disease." Agricultural Sciences 2015; 6: 42-70. (Download)
    17. Wendy A Morley and Stephanie Seneff. "Diminished brain resilience syndrome: A modern day neurological pathology of increased susceptibility to mild brain trauma, concussion, and downstream neurodegeneration." Surg Neurol Int 18 Jun 2014;5:97. (Download)
    18. CA Shaw, S Seneff, SD Kette, L Tomljenovic, JW Oller Jr., and RM Davidson. "Aluminum-Induced Entropy in Biological Systems: Implications for Neurological Disease." Journal of Toxicology 2014: Article ID 491316. (Download)
    19. CA Shaw, SD Kette, RM Davidson, and S Seneff. "Aluminum’s Role in CNS-immune System Interactions leading to Neurological Disorders." Immunome Research 2013; 9:069. doi: 10.4172/1745-7580.1000069. (Download)
    20. Anthony Samsel and Stephanie Seneff, " Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance." Interdiscip Toxicol. 2013; 6(4): 159-184. (Download)
    21. Anthony Samsel and Stephanie Seneff, "Glyphosate's Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases" Entropy 2013, 15(4), 1416-1463; doi:10.3390/e15041416 (Download)
    22. Robert M. Davidson, Ann Lauritzen and Stephanie Seneff, "Biological Water Dynamics and Entropy: A Biophysical Origin of Cancer and Other Diseases" Entropy 2013, 15, 3822-3876; doi:10.3390/ e15093822 (Download)
    23. Stephanie Seneff, Ann Lauritzen, Robert Davidson and Laurie Lentz-Marino, "Is Encephalopathy a Mechanism to Renew Sulfate in Autism?" Entropy 2013, 15, 372-406; doi:10.3390/e15010372 (Download)
    24. Stephanie Seneff, Ann Lauritzen, Robert Davidson and Laurie Lentz-Marino, "Is Endothelial Nitric Oxide Synthase a Moonlighting Protein Whose Day Job is Cholesterol Sulfate Synthesis? Implications for Cholesterol Transport, Diabetes and Cardiovascular Disease." Entropy 2012, 14, 2492-2530; doi:10.3390/e14122492 (Download)
    25. Stephanie Seneff, Robert M. Davidson and Jingjing Liu, "Is Cholesterol Sulfate Deficiency a Common Factor in Preeclampsia, Autism, and Pernicious Anemia?" Entropy 2012, 14, 2265-2290; doi:10.3390/e14112265 (Download)
    26. Samantha Hartzell and Stephanie Seneff, "Impaired Sulfate Metabolism and Epigenetics: Is There a Link in Autism?" Entropy 2012, 14, 1953-1977; doi:10.3390/e14101953 (Download)
    27. Stephanie Seneff, Robert M. Davidson, and Jingjing Liu, "Empirical Data Confirm Autism Symptoms Related to Aluminum and Acetaminophen Exposure," Entropy 2012, 14, 2227-2253; doi:10.3390/e14112227 (Download)
    28. Robert M. Davidson, and Stephanie Seneff, "The Initial Common Pathway of Inflammation, Disease, and Sudden Death," Entropy 2012, 14, 1399-1442; doi:10.3390/e14081399 (Download)
    29. Stephanie Seneff, Glyn Wainwright, and Luca Mascitelli, "Nutrition and Alzheimer's Disease: The Detrimental Role of a High Carbohydrate Diet," European Journal of Internal Medicine 22 (2011) 134-140; doi:10.1016/j.ejim.2010.12.017 (Download)
    30. Stephanie Seneff, Glyn Wainwright, and Luca Mascitelli, "Is the Metabolic Syndrome Caused by a High Fructose, and Relatively Low Fat, Low Cholesterol Diet?" Archives of Medical Science, 2011; 7, 1: 8-20; doi:10.5114/aoms.2011.20598 (Download)
    31. Stephanie Seneff, Robert Davidson, and Luca Mascitelli, "Might cholesterol sulfate deficiency contribute to the development of autistic spectrum disorder?" Medical Hypotheses, 8, 213-217, 2012. (Download)

    Interviews and Webinars

  • Webinar on glyphosate, oxalate and sulfate with Julie Matthews, March 2017. Slide Presentation Slides
  • WAPF interview on statin drugs, heart disease and glyphosate. WAPF Nov. 2015
  • You must be nuts! Puppets Alph, Beel & Chah-Lee learn about the business of dementia from a series of online interviews by Obhi Chatterjee. Published Dec. 21, 2014.
  • Interview with Richard Longland on glyphosate and autism (integrated with slides): (Part One) (Part Two)
  • Legal Edition television interview with Mary Kay Elloian on glyphosate and Roundup. November 3, 2014.
  • Radio Interview with Dr. Cindy Anderson on FTNS radio January 23, 2013.
  • Dr. Hildy®, Stephanie Seneff, and Atty. Keith Landrum, MD: VACCINES: Past, Present, Future | One Cell One Light® Radio February 18, 2015
  • AutismOne Presentations, 2014, 2015 and 2016.

  • Presentation on Wednesday, May 25, 2016 at AutismOne in Chicago (Powerpoint Slides) (PDF Version)
  • Presentation on Friday, May 27, 2016 at AutismOne in Chicago (Powerpoint Slides) (PDF Version)
  • Presentation on Wednesday, May 20, 2015 at AutismOne in Chicago (Powerpoint Slides) (PDF Version)
  • Presentation on Thursday, May 21, 2015 at AutismOne in Chicago (Powerpoint Slides) (PDF Version)
  • Presentation on glyphosate on May 24, 2014 at AutismOne in Chicago (Powerpoint Slides) (PDF Version) (Video Presentation)

    TV Interviews with Mary Kay Eloian of the Legal Edition

  • Statin Drugs
  • GMOs and Glyphosate
  • Vaccines: Part 1
  • Vaccines: Part 2
  • Presentations at Yale's Unite For Sight Global Health & Innovation Conference.

  • Apr. 22, 2017. 14th Annual Unite for Sight Conference. Glyphosate Pretending to be Glycine: Devastating Consequences. (Powerpoint Slides) (PDF Version)

  • Apr. 16, 2016. 13th Annual Unite for Sight Conference. Roundup and Autism: Why Correlation IS Causation This Time. (Powerpoint Slides) (PDF Version)

  • Mar 29, 2015. 12th Annual Unite for Sight Conference. Why Soy is Unhealthy: It's NOT what you Think! (Powerpoint Slides) (PDF version)

  • April 12, 2014. 11th Annual Unite For Sight Conference. (Powerpoint Slides) (PDF Version)

  • Weston Price Foundation Wise Traditions Articles and Presentations

  • Why We Need to Reexamine the Risk/Benefit Tradeoffs of Vaccines. WAPF Article, Summer, 2015.

  • Cancer to the rescue? How Tumor Cells Work Overtime to Restore Vascular Health. WAPF Article, January 20, 2014.

  • Podcast on glyphosate - interview with Hilda Labrada Gore. Podcast, November, 2016

  • Powerpoint Presentations at the Weston A. Price Wise Traditions 17th Annual Conference Montgomery, Alabama November 11-14, 2016.
    Microcephaly in Brazil: Is it Really Just Zika? (Part I Slides) (Part II Slides)

  • Powerpoint Presentations at the Weston A. Price Wise Traditions 16th Annual Conference Indianapolis November 13-16, 2015.
    1. Folic Acid Supplementation: Why This is Not a Good Idea (Powerpoint Slides) PDF Version)
    2. Cholesterol Sulfate, Electricity and the Vasculature (Powerpoint Slides) (PDF Version)
  • Powerpoint Presentations at the Weston A. Price Wise Traditions 15th Annual Conference Indianapolis November 7-10, 2014.
    Pesticides, Antibiotics, Vaccines and Pharmaceuticals: Are They the Cause of our Current Health Crisis?
    1. Nutrition (Powerpoint Slides) (PDF Version)
    2. Pesticides: Focus on Roundup (Powerpoint Slides) (PDF Version)
    3. Vaccines, Antibiotics, and Microbes (Powerpoint Slides) (PDF Version)
    4. Pharmaceutical Drugs: Focus on Statins (Powerpoint Slides) (PDF Version)

  • Powerpoint Presentations at the London Chapter's Weston Price Foundation Wise Traditions Conference in February, 2014.
    1. GMOs and Roundup: a Marriage Made in Hell (Powerpoint Slides) (PDF Version)
    2. Cholesterol, Sulfate and Heart Disease (Powerpoint Slides) (PDF Version)
  • Powerpoint Presentations at the Weston A. Price Wise Traditions Conference in Atlanta, GA, November 2013.
    1. Introduction (Powerpoint Slides) (PDF Version)
    2. Cholesterol Sulfate (Powerpoint Slides) (PDF Version)
    3. Gut Microbes: How They Help Us Out (Powerpoint Slides) (PDF Version)
    4. Autism, Depression, and Alzheimer's Disease (Powerpoint Slides) (PDF Version)
    5. Glyphosate: The Elephant in the Room (Powerpoint Slides) (PDF Version)
    6. Nutrition: Facts and Fiction (Powerpoint Slides) (PDF Version)
  • Powerpoint Presentations at the Weston A. Price Wise Traditions Conference in Santa Clara, CA, in November, 2012.
    1. Taurine: A Mysterious Molecule with Intriguing Possibilities (Powerpoint Slides) (PDF Version)
    2. Nutrition, Toxins, and Health: Facts and Speculation. Part I: Nutrition (Powerpoint Slides) (PDF version)
    3. Nutrition, Toxins, and Health: Facts and Speculation. Part II: Biology (Powerpoint Slides) (PDF Version)
  • Powerpoint Presentations at the London Chapter's Weston Price Foundation Wise Traditions Conference in March, 2012.
    1. Let The Sun Shine In! (Powerpoint Slides)
    2. The Silver Lining in Chronic Disease (Powerpoint Slides)
    3. Autism, Alzheimer's and Depression: A Shared Underlying Pathology and Treatment (Powerpoint Slides)
    4. Glossary of Terms (Pdf File)
  • Powerpoint Presentations at Weston Price Foundation's 2011 Wise Traditions Conference in Dallas, Texas.
    1. Cholesterol, Sulfur, Lactate, and Sunlight: a New Paradigm for Health (Powerpoint Slides)
    2. Autism, Vaccines, and Cholesterol Sulfate (Powerpoint Slides)
    3. How Statins Really Work Explains Why They Don't Really Work (Powerpoint Slides)

    Essays on health

    1. Low Fat Diet and Sunscreen: A Recipe for Disaster
    2. Why You should Think Twice before Starting Statin Therapy
    3. Statins, Pregnancy, Sepsis, Cancer, Heart Failure: A Critical Analysis.
    4. APOE-4: The Clue to Why Low Fat Diet and Statins may Cause Alzheimer's.
    5. Statins and Myoglobin: How Muscle Pain and Weakness Progress to Heart, Lung and Kidney Failure
    6. Morbid Obesity, Vitamin D Deficiency, and Swine Flu.
    7. The Obesity Epidemic: is the Metabolic Syndrome a Nutritional Deficiency Disease? Georgian translation created by Irakli Nishnianidze
    8. Is ADHD Caused by Insufficient Dietary Fat?
    9. Could Sulfur Deficiency be a Contributing Factor in Obesity, Heart Disease, Alzheimer's and Chronic Fatigue Syndrome?
    10. How Statins Really Work Explains Why They Don't Really Work.
      (Acrobat (PDF) file )

    Video and Audio Clips

    1. Video Clip illustrating ability for student to create flash cards and use them in a simple speech-enabled interactive game on the Web (Video Clip )
    2. Video Clip illustrating simple speech-enabled card game, Rainbow Rummy, where students use vocabulary of named objects and colors communicatively. (Video Clip )
    3. Video Clip illustrating social game where two people compete against each other in Rainbow Rummy card game. (Video Clip )
    4. Video clip illustrating spoken interaction with language learning weather system (Video Clip )
    5. Audio clip of student's original speech "shang4 hai3 ne5" (Waveform file )
    6. Audio clip of student's speech with tones repaired through phase vocoder transformations (Waveform file )

    Selected Other Papers

    1. Jingjing Liu and Stephanie Seneff, A Dialogue System for Accessing Drug Reviews, ASRU, Hawaii, December, 2011.
      (Acrobat (PDF) file )
    2. Jingjing Liu, Alice Li and Stephanie Seneff, Automatic Drug Side Effect Discovery from Online Patient-Submitted Reviews: Focus on Statin Drugs, IMMM, Barcelona, Spain, October, 2011.
      (Acrobat (PDF) file )
    3. Speech-enabled Card Games for Incidental Vocabulary Acquisition in a Foreign Language, Speech Communication, Special Issue on Applications to Language Learning 51(10), 1106-1123, 2009.
      (Online Version )
    4. The Use of Subword Linguistic Modeling for Multiple Tasks in Speech Recognition, Speech Communication, Vol. 42, No. 3-4, pp. 373--390, 2004.
      (Acrobat (PDF) file )
    5. The Use of Linguistic Hierarchies in Speech Understanding, Keynote Address, ICSLP '98.
      (Acrobat (PDF) file )
    6. ANGIE: A New Framework for Speech Analysis Based on Morpho-Phonological Modelling, ICSLP '96
      (Acrobat (PDF) file )
    7. Response Planning and Generation in the Mercury Flight Reservation System. Computer Speech and Language, Vol. 16, 2002.
      (Acrobat (PDF) file )
    8. Automatic Acquisition of Names Using Speak and Spell Mode in Spoken Dialogue Systems. HLT 2003.
      (Acrobat (PDF) file )
    9. Galaxy-II: A Reference Architecture for Conversational System Development. ICSLP '98.
      (Acrobat (PDF) file )
    10. Integration of Hierarchical Linguistic, Prosodic, and Phonological Constraints in the Jupiter Domain. ICSLP '98.
      (Acrobat (PDF) file )

    Diane Harper

    MD, MPH, MS

    Diane Harper

    MD, MPH, MS

    Biografia:


    Diane Medved Harper, MD, MPH, MS is the Director of the Gynecologic Cancer Prevention Research Group and is a Professor of Community and Family Medicine, Biomedical and Health Informatics and Obstetrics and Gynecology at University of Missouri Kansas City School of Medicine. Her research has been well funded from a mix of federal agencies (NCI), state agencies, private foundations, and industrial partners; covering research in all aspects of cervical cancer prevention and HPV associated diseases: barriers to screening use by underserved and unserved women; leukocyte functions in the cervix; HPV detection methods by self sampling; anal cancers and EGW in MSM; quality of life assessments of screening, colposcopy and treatment methods, colposcopy improvements including frontier work in optical tissue diagnosis of CIN disease by fluorescent techniques and by acetowhitening kinetics; a member of the Steering Committee of ALTS; telecolposcopy; cost effectiveness analyses for screening and triage of cervical cancer programs; Shared Decision Making Programs for cervical cancer screening, follow up, treatment and prevention programs; and HPV vaccination work. She has received several national awards for her teaching, clinical work and research.

     

    Academic positions:


    1. 2011: Professor, Adjunct Graduate Faculty, UMKC School of Medicine
    2. 2009: Vice-Chair, Research, Department of Community and Family Medicine, UMKC School of Medicine
    3. 2008: Professor, Department of Community & Family Medicine, UMKC School of Medicine
    4. 2008: Professor, Department of Obstetrics and Gynecology, UMKC School of Medicine
    5. 2008: Professor, Department of Biomedical and Health Informatics, UMKC School of Medicine
    6. 2006: Professor, Department of Women’s and Gender Studies Program, Dartmouth College
    7. 2006: Professor, Department of Community and Family Medicine, Dartmouth Medical School
    8. 2006: Professor, Department of Obstetrics /Gynecology, Dartmouth Medical School
    9. 2003: Associate Professor, Department of Women’s and Gender Studies Program, Dartmouth College
    10. 2000: Associate Professor, Department of Community and Family Medicine, Dartmouth Medical School
    11. 2000: Associate Professor, Department of Obstetrics /Gynecology, Dartmouth Medical School
    12. 1996: Assistant Professor, Department of Community and Family Medicine, Dartmouth Medical School
    13. 1996: Assistant Professor, Department of Obstetrics /Gynecology, Dartmouth Medical School
    14. 1996: Clinical Associate Professor, Department of Obstetrics /Gynecology, UMKC School of Medicine
    15. 1996: Associate Professor, Department of Community and Family Medicine, UMKC School of Medicine
    16. 1990: Assistant Professor, Department of Community and Family Medicine, UMKC School of Medicine
    17. 1981: Research Assistant, Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA
    18. 1980: Teaching Assistant, Department of Materials Science and Engineering,
    Massachusetts Institute of Technology, Cambridge, MA

    Awards and Honors

    1. 1976: First Place Award. Chemistry Division, The International Science and Engineering Fair, for Medved DL. The Oil Sorption Capacity of Three Foams
    2. 1977: London Youth International Science Fortnight, for Medved DL. The Oil Sorption Capacity of Three Foams.
    3. 1978: United States National Women's Crew Team
    4. 1979: Betsy Schumaker Award for the most outstanding woman athlete at Massachusetts Institute of Technology who has competed for the Massachusetts Institute of Technology and has exhibited notable athletic accomplishment beyond the collegiate competitions
    5. 1980: United States Olympic Finalist for Women's Crew Team, [Olympics boycotted]
    6. 1990: Most Outstanding Third-Year Family Medicine Resident Award presented for performance in Internal Medicine at Bethany Medical Center-KUMC
    7. 1991: Jack L. Mulligan, MD Teacher of the Year Award, University of Missouri- Kansas City School of Medicine presented for excellence in teaching which has met the highest standards of
    resident education in Family Medicine
    8. 1994: Saks Fifth Avenue Leadership Recognition Award for Meritorious Community Leadership for Promotion of Early Detection of Breast Cancer. The Kansas City Leadership Summit:  The Challenge of Breast Cancer
    9. 1994: ACLS Honor Roll. Recognition to the medical director and the hospital staff coordinating Advanced Cardiac Life Support Provider and Instructor classes for those hospitals whose medical, nursing and emergency room staff have maintained current ACLS training among at least 85% providers
    10. 1994: Colposcopy Recognition Award, American Society of Colposcopy and Cervical Pathology
    11. 1995, 1998, 2001, 2004: Physician’s Recognition Award.  American Medical Association Award
    for more than 600 continuing medical education units earned in 36 months.
    12. 1995: UKC Trustees’ Faculty Fellowship. $10,000 award
    13. 1995: Award for Research Grant Development in Family Medicine from the North American Primary Care Research Group
    14. 1988: Second Place. Housestaff Research in Medicine Symposium for Harper DM, Liese BS, Johnson CA. Symphysis-Fundus Height as a Predictor of Labor Pattern and Delivery Method. University of Kansas Medical School
    15. 1988: Outstanding Research Award. Kansas Academy of Family Physicians 38th Annual Scientific Assembly for Harper DM, Liese BS, Johnson CA. Symphysis-Fundus Height as a Predictor of Labor Pattern and Delivery Method. University of Kansas Medical School
    16. 1988: Second Place. Scientific Exhibits, 1988, American Academy of Family Physicians 40th Annual Scientific Assembly for Harper DM, Liese BS, Johnson CA. Symphysis-Fundus Height as a Predictor of Labor Pattern and Delivery Method. University of Kansas Medical School
    17. 1990: First Place. Ciba-Geigy Resident Award, Kansas Academy of Family Physicians 40th Annual Scientific Assembly for Harper DM, Liese BS, Johnson CA, Dolezal JM, Harper WH. Cesarean Section Predicted by Parity, Age, Height, Symphysis-Fundus Height and Past Macrosomia
    18. 1990: Second Place. Scientific Exhibits, American Academy of Family Physicians 42nd Annual Scientific Assembly for Harper DM, Liese BS, Johnson CA, Dolezal JM, Harper WH. Cesarean Section Predicted by Parity, Age, Height, Symphysis-Fundus Height and Past Macrosomia
    19. 1990: First Place. Scientific Research Presentations, American Academy of Family Physicians 42nd Annual Scientific Assembly for Harper DM, Liese BS, Johnson CA, Dolezal JM, Harper WH. Cesarean Section Predicted by Parity, Age, Height, Symphysis-Fundus Height and Past Macrosomia
    20. 1992: American Cancer Society Cancer Control Career Development Award. Provided funding for MPH Degree and Stanford training in MDM.

     

    Research interests:


    HPV associated diseases; telemedicine; shared decision making; cost effectiveness analysis; vaccinology

     

    Any other information:


    Research Publications, peer reviewed:

    1. McElroy P, Medved DL, Roylance D. Weathering of Sheet Molding Compounds. In:  Environmental Degradation of Engineering Materials in Aggressive Environments. Proceedings of the Second International Conference on Environmental Degradation of Engineering Materials 473-479, September 21-23, 1981.
    2. Harper DM, Walstatter BS, Lofton BJ.  Anesthetic Blocks for Loop Electrosurgical Excision Procedure.  J Fam Pract 39(3):249-256, 1994.
    3. Harper DM.  Pain and Cramping Associated with Cryosurgery.  J Fam Pract 39(6):551-557, 1994.  
    4. Harper, DM, Johnson CA, Harper WH, Liese BS.  Prenatal Predictors of Cesarean Section due to Labor Arrest.  Arch Gynecol Obstet 256(2):67-74, 1995.  
    5. Harper DM.  The Paracervical Block Diminishes Cramping Associated with Cryosurgery.  J Fam Pract 44:71-75, 1997.
    6. Comninellis NB, Harper DM.  Does Comprehensive Preventive Medicine Training Enhance Clinical Prevention?  Fam Med 29(2):112-114, 1997.
    7. Ferris DG, Harper DM. The Efficacy of Topical Benzocaine Gel in Providing Anesthesia Prior to Cervical Biopsy and Endocervical Curettage.  Journal of Lower Genital Tract Disease 1(4):221-227, 1997.
    8. Ferris DG, Cox JT, Burke L, Litaker MS, Harper DM, Campion MJ, Greenberg MD, Wun LM, McShane L. Colposcopy Quality Control: Establishing Colposcopy Criterion Stands for the NCI ALTS Trial. Journal of Lower Genital Tract Disease 2(4):195-203, 1998.
    9. Pogue BW, Burke GC, Weaver J, Harper DM.  Multi-wavelength digital colposcopy to aid early detection of cervical cancer. Biomedical Optical Spectroscopy and Diagnostics (Vol 22) in Therapeutic Laser Applications, Trends in Optics and Photonics book series, pp. 118-21, 1998.
    10. Stern JE, Givan AL, Gonzalez JL. Harper DM, White HD, Wira CR.  Leukocytes in the cervix: A Quantitative Evaluation of Cervicitis.  Obstet Gynecol 91:987-92, 1998.
    11. Harper DM, Cobb JL.  Cervical Mucosal Block Effectively Reduces the Pain and Cramping from Cryosurgery.  J Fam Pract 47:285-289, 1998.
    12. Tobia DM, Shamos EF, Harper DM, Walch SE, Currie JL.  The Benefits of Group Music at the 1996 Music Weekend for Women with Cancer. J Cancer Educ 14:115-119, 1999.
    13. Harper DM, Cobb JL.  Is it Cost Effective to Use a Mucosal or Paracervical Block to Relieve the Pain and Cramping from Cryosurgery?  A Decision Model. J Fam Pract 48:285-290, 1999.
    14. Harper DM, Hildesheim A, Cobb JL, Greenberg M, Vaught J, Lorincz A.  Collection Devices for Human Papillomavirus.  J Fam Pract 48:531-535, 1999.  
    15. Pogue BW, Mycek MA, Harper DM.  Image Analysis for Discrimination of Cervical Neoplasia.  J Biomed. Optics 5(1):72-82, 2000.
    16. Taylor LA, Sorensen SV, Ray NF, Halpern MT, Harper DM.  Cost effectiveness of the conventional Papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors. Arch Fam Med 9:713-721, 2000.
    17. Harper, DM, Moncur MM, Harper WH, Burke GC, Rasmussen CA, Mumford MC.  The technical performance and clinical feasibility of telecolposcopy. J Fam Pract 49:623-627, 2000.
    18. Harper DM, Parke KA, Cobb JL Moncur MM.  Self-reported desire to improve colposcopic impressions.  Archives of Gynecology and Obstetrics 264:137-142, 2000.
    19. Harper DM, Mayeaux EJ, Daaleman TP, Woodward LD, Ferris DG, Johnson CA. The Natural History of Cervical Cryosurgical Healing: Debridement of the Cervical Eschar has Minimal Effect. J Fam Pract 49:694-700, 2000.
    20. Harper DM, Mayeaux EJ, Daaleman TP, Johnson CA.  Healing Experiences after Cervical Cryosurgery. J Fam Pract 49:701-706, 2000.
    21. Pogue BW, Kaufman HB, Zelenchuk A, Harper W, Burke GC, Burke EE, Harper DM.  Analysis of acetic acid-induced whitening of high-grade squamous intraepithelial lesions.  J Biomed Optics 6:397-403, 2001.  
    22. Harper DM, Noll WW, Belloni DR, Cole BF.  Randomized Clinical Trial of PCR Determined HPV Detection Methods:  Self-Sampling vs. Clinician-Directed -- Biological Concordance and Women’s Preferences.  Am J Obstet Gynec 186:365-373, 2002.
    23. Harper DM, Noll WW, Raymond R, Duncan LT, Belloni DR, Cole BF.  Tampon samplings with longer cervico-vaginal cell exposures are equivalent to two consecutive swabs for the detection of high-risk HPV. Sexually Transmitted Diseases 29: 628-636, 2002.
    24. Harper DM, Raymond M, Noll WW, Belloni DR, Cole BF.  Factors affecting the detection rate of human papillomavirus. Ann Fam Med 1: 221-7, 2003.
    25. Gilbert LK, Alexander L, Grosshans J, Jolley L. [American Social Health Association. DM Harper is member of HPV Scientific Advisory Committee for ASHA conducting this study, although not a member of the writing committee, and has met the qualifications for authorship: concept design, manuscript reviews and approval of final manuscript submitted.]  Answering frequently asked questions about HPV.  Sex Trans Dis 30(3):193-4, 2003.
    26. Becker HI, Longacre MR, Harper DM.  Beyond the Pap: Assessing Women’s Priorities for Annual Exams.  J Women’s Health 13:791-798, 2004.  
    27. Harper DM, Schmid-Saugeon P, Zelenchuk A, Pitts JD, Kaufman HB. Kinetic Patterns of Colposcopic acetowhitening associated with cervical pathology.  Obstet Gynecol 103:18S, 2004.
    28. Harper DM, Schmid-Saugeon P, Zelenchuk A, Pitts JD, Kaufman HB. Quantitative Measurements of acetowhitening may provide an adjunct to colposcopy to identify cervical intraepithelial neoplasia 2 and 3.  Obstet Gynecol 103:19S, 2004.
    29. Harper DM, Huh WW, Alvarez RD, Guido RS, McIntyre-Seltman K, Schomacker KT.  The Effect of the Menstrual Cycle phases on the optical algorithms developed from diffuse reflectance.  Obstet Gynecol 103:22S, 2004.
    30. Garcia F, Huh WW, Cestero RM, Gold MA, McIntyre-Seltman K, Harper DM.  Effect of age, acetic acid application method, and target distance on optical detection of CIN 2/3.  Obstet Gynecol 103:81S, 2004.
    31. Huh WK, Cestero RM, Garcia FA, Gold MA, Guido RS, McIntyre-Seltman K, Harper DM, Burke L, Sum ST, Flewelling RF, Alvarez RD. Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. Am J Obstet Gynecol 190(5):1249-57, 2004.
    32. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, Carvalho N, Rotelli C, Teixeira J, Blatter M, Korn A, Quint Wim, Dubin G for the GlaxoSmithKline HPV Vaccine Study Group.   Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.  Lancet 364: 1757-65, 2004.
    33. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic Quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.  Lancet Oncology. 6(5):271-8, 2005.
    34. Wiley DJ, Harper DM, Elashoff D, Silverberg MJ, Kaestle C, Cook RL, Heilemann M, Johnson L. How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts.  International Journal of STD & AIDS. 16(3):203-11, 2005.
    35. Monsonego, J. [Harper DM]. EUROGIN. HPV infections and cervical cancer prevention. Priorities and new directions. Highlights of EUROGIN 2004 International Expert Meeting, Nice, France, October 21-23, 2004. Gynecologic Oncology. 96(3):830-9, 2005.
    36. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial (vol 60, pg 171, 2005).  Obstetrical & Gynecological Survey 60(7):484-484, 2005.
    37. Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G on behalf of the HPV Vaccine Study Group.  Sustained Efficacy up to 4.5 years of a bivalent L1 virus like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial.  Lancet 2006;367:1247-55.
    38. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.  Vaccine. 2006 Jul 7;24(27-28):5571-83.
    39. Garland S, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo F, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, and Koutsky LA, for the FUTURE I Investigators.  Efficacy of a quadrivalent HPV (Types 6/11/16/18) L1 VLP Vaccine against external anogenital, vaginal, and cervical disease. A randomized controlled trial.  N Engl J Medicine.  2007: 356(19):1928-43.  
    40. Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Esser MT, Vuocolo SC, Nelson M, Railkar R, Sattler C, and Barr E on behalf of the 012 Study Investigators.  An evaluation of non-inferiority in antibody response to human papillomavirus (HPV) 16 in subjects vaccinated with monovalent (HPV 16) and quadrivalent (HPV 6, 11, 16, 18) L1 virus like particle vaccines.  Clinical and Vaccine Immunology. 2007 Jun;14(6):792-5.  
    41. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM,  Perez G, Koutsky LA, Garland SM, Harper DM, Tang GWK, Ferris DG,  Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Paavonen J.  Efficacy of a quadrivalent prophylactic human papillomavirus (types 6/11/16/18) L1 virus like particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three clinical trials.  Lancet. 2007 May 19;369(9574):1693-702.
    42. Saslow D. Castle PE. Cox JT. Davey DD. Einstein MH. Ferris DG. Goldie SJ. Harper DM. Kinney W. Moscicki AB. Noller KL. Wheeler CM. Ades T. Andrews KS. Doroshenk MK. Kahn KG. Schmidt C. Shafey O. Smith RA. Partridge EE. Gynecologic Cancer Advisory Group. Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA: a Cancer Journal for Clinicians. 57(1):7-28, 2007 Jan-Feb.
    43. Cobb KL, Bachrach LK, Sowers M, Nieves J, Greendale GA, Kent KK, Brown WB, Pettit K, Harper DM, Kelsey JL.  Randomized trial of the effect of oral contraceptives on bone mass and stress fractures in female runners.  Medicine & Science in Sports & Exercise.  2007 Sep;39(9):1464-73.
    44. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal K, Harper DM, Markowitz L. Human Papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organization. 2007 Sep;85(9):719-26.
    45. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GAM, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SI, Lehtinen MO, Dubin G for the HPV PATRICIA study group.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.  Lancet 2007;369:2161-70.   
    46. Wiley DJ, Elashoff D, Masongsong EV, Harper DM, Gylys KH, Silverberg MJ,  Cook RL,  Johnson-Hill LM. Smoking enhances risk for new external genital warts in men. International Journal of Environmental Research & Public Health. 2009 Mar;6(3):1215-34.
    47. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A.  Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.  Lancet. 2009 Dec 12;374(9706):1975-85.
    48. FUTURE I/II Study Group (Harper DM), Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010 Jul 20;341:c3493.
    49. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators (Harper DM).   Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94.
    50. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, Joura EA, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM; for the FUTURE I (Harper DM), II and III Investigators. The accuracy of colposcopic biopsy: Analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer 2011 Mar 15;128(6):1354-62.

    Sin Hang Lee

    MD

    1956 MD, Wuhan Medical College, China

    1964 Chief resident in pathology, New York Hospital (Papanicolaou’s Lab)

    1966 Certified, American Board of Pathologist, F.R.C.P.(C)

    1966- Practicing diagnostic cancer pathology and clinical microbiology. Patentee of first estrogen-receptor assay for breast cancer (PMA) and a specific mycoplasma pneumoniae serologic test (510K), both approved by FDA. Recent publications:

    1)Lee SH, Vigliotti VS, Vigliotti JS, Pappu S. Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories. Infect Agent Cancer 2007; 2:11.

    2) Lee SH, Vigliotti VS, Pappu S. DNA Sequencing Validation of Chlamydia trachomatis and Neisseria gonorrhoeae Nucleic Acid Tests. Am J Clin Pathol. 2008; 129:852-859

    .

    3) Lee SH, Vigliotti VS, Pappu S. Human papillomavirus (HPV) infection among women in a representative rural and suburban population of the United States. Inter J Gyn Ob. 2009; 105: 210-214.

    4) Lee SH, Vigliotti VS, Vigliotti JS, Pappu S. Molecular tests for human papillomavirus (HPV), Chlamydia trachomatis and Neisseria gonorrhoeae in liquid-based Pap cytology specimen . BMC Women’s Health 2009; 9:8.

    5) Lee SH, Vigliotti VS, Vigliotti JS, Pappu S. Validation of human papillomavirus genotyping by signature DNA sequence analysis. BMC Clin Pathol. 2009; 9:3. Pathologist, Milford Hospital, Milford, CT 203 876-4258. Director, Milford Medical Lab. President, HiFi DNA Tech, LLC, Trumbull, CT - PCR/DNA sequencing in hospitals.

    Inappropriate use indication for FDA-approved HPV DNA test promotes unnecessary cervical biopsies in US

    More than 95% of referrals to colposcopy for diagnostic workup are false positive and/or potentially excessive (unnecessary). Screening with combined cytologic and HPV testing, regardless of patient age, leads to the highest number of excessive colposopic referrals. [Stout NK et al. Department of Health Policy and Management, Harvard School of Public Health. 2008]

    The estimated 1992 annual cost of the overused colposcopic biopsy was at $6 billion. The number of colposcopic biopsies increased markedly since. [Lousuebsakul V et al. Is colposcopic biopsy overused among women with a cytological diagnosis of atypical squamous cells of undetermined significance (ASCUS)? J Women’s Health (Larchmt). 2003; 12:553-9.]

    Since 2003, more ASCUS diagnoses have been made by pathologists after the HPV DNA test was approved for triage to 4-quadrant cervical biopsies. Now the unnecessary biopsies may cost more than $10 billion in 2009.

    Cost due to psychological and physical trauma to patients not counted.

    Cost for complications, such as excessive bleeding and infections not counted.

    Cost of loss of work days of the patients not counted.

    Inappropriate 2003 FDA (PMA) approval of expanded use of HPV test

    At the open session microbiology devices panel meeting, March 8, 2002, the device’s modified indications were presented “for use as a general population screening test in conjunction with the Papanicolaou (Pap) smear for women age 30 and older, as an aid to determining the absence of high-grade cervical disease or cancer.”

    In the approval letter for Digene Hybrid Capture HC2 High-Risk HPV DNA

    Test dated March 31, 2003 and signed by OIVD, the test was approved for: “1. To screen patients with ASCUS Pap smear results to determine the need for referral to colposcopy. The results of this test are not intended to prevent women from proceeding to colposcopy.” (Approved by Steven Gutman/Elizabeth Mansfield, over the objections of the FDA review scientists and the Panel members) ? Connected events

    At the open session microbiology devices panel meeting, March 8, 2002, the device’s modified indications were presented “for use as a general population screening test in conjunction with the Papanicolaou (Pap) smear for women age 30 and older, as an aid to determining the absence of high-grade cervical disease or cancer.”

    Connected events

    In the approval letter for Digene Hybrid Capture HC2 High-Risk HPV DNA Test dated March 31, 2003 and signed by OIVD, the test was approved for: “1. To screen patients with ASCUS Pap smear results to determine the need for referral to colposcopy. The results of this test are not intended to prevent women from proceeding to colposcopy.”(Approved by Steven Gutman/Elizabeth Mansfield, over the objections of the FDA review scientists and the Panel members)

    Digene Corp. DEF 14A SEC Filing under How chief executive officer is compensated: (1) 2001: for assembling a team for Digene’s progress with FDA…in entering into agreements with strategic partners ; (2) 2004: for Digene’s progress with FDA approvals and his success ..Digene’s diagnostic test products for HPV.

    FDA CDRH OIVD official website April 22, 2003 by Mark A. Del Vecchio, Director, Regulatory and Clinical Affairs, Digene Corporation -How to work with FDA: Important not to surprise the Agency. FDA interaction (asymmetrical in FDA practice).

    Elizabeth Mansfield: Director of Regulatory Affairs, Affymetrix, Inc. (J Mol Diagn 2005; 7:2-7, accepted Nov 2, 2004; April 11-13, 2005 FDA-sponsored Workshop), June 8, 2004 Bio 2004 Breakout Sessions OIVD/FDA Scientific Reviewer.

    Letter dated July 11, 2003 from Affymetrix, Inc. Senior Vice President to Elizabeth Mansfield, PhD, FDA: Developing Multiplex Test Policy.

    What to do to protect public health

    Conduct an open session microbiology advisory panel meeting to review the indications of use in the March 31, 2003 approval letter for HPV test.

    Review in vitro(untainted glass is transparent) devices strictly based on the science governed by the law of physics and mathematical probabilities.

    Avoid pseudoscience, such as using subjective clinical data for validation of in vitrotests (the least burdensome provision of the FDAMA of 1997).

    Respond even-handedly to avoid asymmetrical application of medical device law and regulations, or its public perception.

    Confine the role of OIVD to regulate commercial medical devices, not the tests developed under the regulations of CLIA 88’(OIVD cannot keep up with the advance of medical science in this era of information explosion).

    Prohibit managers/policy makers from taking employments or consultation fees from the OIVD-regulated industry for 5 years after they leave FDA.

    Supportive documents submitted

    1)Lee SH et al. Infect Agent Cancer 2007; 2:11.

    2)LeeSHetal.AmJClinPathol.2008;129:852-859.

    3)LeeSHetal.InterJGynOb.2009;105:210-214.

    4)LeeSHetal..BMCWomen’sHealth2009;9:8.

    5)LeeSHetal..BMCClinPathol.2009;9:3

    6)StoutNKetal.HarvardSchoolofPublicHealth.ArchInternMed2008;168:1881-1889.

    7)LousuebsakulVetal.JWomen’sHealth(Larchmt).2003;12:553-9.

    8)Opensessionmicrobiologydevicespanelmeeting,March8,2002.

    9)FDAOIVDapprovalletterMarch31,2003expandeduseofHPVtest(Reviewer:E.Mansfield).

    10)DigeneCorp.DEF14ASECFilingdate9/26/2001EDGAROnline.

    11)DigeneCorp.DEF14ASECFilingdate9/23/2004EDGAROnline.

    12)FDAOIVDofficialwebsiteApril22,2003byDigene’sdirectorofregulatory&clinicalaffairs.

    13) Mol Diagn 2005; 7:2-7 (accepted Nov 2, 2004) stated E. Mansfield was with Affymetrix, Inc.

    14) April 11-13, 2005 Workshop co-sponsored by FDA: E. Mansfield was listed as Director of Regulatory Affairs, Affymetrix Inc.

    15) June 8, 2004 Bio 2004 Breakout Sessions: E. Mansfield was OIVD/FDA Scientific Reviewer.

    16) Letter dated July 11, 2003 from Affymetrix, Inc. to Elizabeth Mansfield, PhD, FDA, showing an FDA employee was to be an employee of a manufacturer she was regulating on behalf of FDA.

    17) Han J. Harvard J Law Tech. 2007; 20:423-441: OIVD regulates without FDA policy or rules.

    18) The New York Times June 25, 2005: Digene’s planned sales price $283 million.

    19) Washington Post June 4, 2007: Digene Corp. sold to Qiagen NV for $1.6 billion.